State-of-the-Art Update on Long COVID and HIV: Pathogenesis, Management, Clinical Trial Updates, and a Patient Perspective

State-of-the-Art Update on Long COVID and HIV: Pathogenesis, Management, Clinical Trial Updates, and a Patient Perspective

Registration Details

  • Virtual Registration: $35.00 (USD)
  • Virtual Registration ends: Thursday, June 22, 2023
  • Virtual Fellows: $15.00 (USD)
  • Virtual Fellows ends: Thursday, June 22, 2023

Course Chairs

Judith S. Currier, MD
University of California Los Angeles
Carlos del Rio, MD
Emory University


Annie Antar, MD, PhD
Johns Hopkins University School of Medicine
Roger Paredes, MD, PhD
Hospital Universitari Germans Trias I Pujol
Jeffrey N. Siegelman, MD
Emory University School of Medicine
Tiffany Walker, MD
Emory University
Kanecia Zimmerman, MD, MPH
Duke University

June 22, 2023

11:00 AM - 3:00 PM ET

Last Modified: Oct 3, 2023 @ 9:37 AM

Program Description

This half-day course will include an overview of the clinical relationship between long COVID and HIV, a case-based panel discussion on the evaluation and management of long COVID, and updates on the latest clinical trials and ongoing gaps in knowledge. The course will also feature a unique perspective on long COVID from a patient’s point of view.

Assessment of Needs

Rapid advances in HIV and COVID-19 require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of long COVID in different clinical settings. Information will be presented through a mix of didactic lectures, clinically relevant cases, and a roundtable discussion developed and led by an expert faculty of HIV/AIDS and COVID-19 clinicians and researchers.


  • Patient Perspective: Long COVID
  • Pathogenesis of Long COVID
  • Evaluation and Management of Long COVID (case-based)
  • Long COVID and HIV
  • Long COVID Clinical Trials

Learning Objectives

After participating in the activity, learners will be able to:

  • Describe the current understanding of long COVID
  • Describe the clinical manifestations of long COVID, including physical and cognitive symptoms
  • Identify the gaps in current knowledge related to the pathogenesis, diagnosis, and management of long COVID, including in people with HIV
  • Describe the current diagnostic criteria and assessment tools for long COVID
  • Outline the latest research in clinical trials on long COVID

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.


Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with or at risk for long COVID, including:

  • Primary care physicians, HIV specialists, and clinicians in pulmonology, immunology, cardiology, nephrology, rheumatology, neurology, or infectious diseases
  • Those who are currently active in HIV or COVID-19 research

This activity is also relevant to nurse practitioners, registered nurses, physicians assistants, physical and occupational therapists, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 7 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 3.75 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 3.75 contact hours (0.375 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-23-250-L02-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.


Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare


Janssen Therapeutics
Theratechnologies Inc.

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at or 415-544-9400.